|
|
|
|
|
|
|
|
Abstract
Objective
There
is limited information concerning the role of relative dose intensity
(RDI) on clinical outcomes in solid tumors. The objectives of our study
were to evaluate the prognostic significance of RDI and predictors of
reduced RDI in women with newly diagnosed advanced stage epithelial
ovarian carcinoma (EOC) treated with platinum-based chemotherapy.
Methods
A
multi-center retrospective study of women with FIGO stage III–IV
epithelial ovarian cancer treated postoperatively with multi-agent
intravenous chemotherapy between 1995 and 2009 was conducted. Data were
obtained to include the first four chemotherapy cycles administered.
Outcomes included: (1) planned and delivered relative dose intensity
(RDI), (2) progression-free (PFS) and overall (OS) survival. Survival
estimates were based on Kaplan and Meier method, and multivariate
analyses were based on logistic regression and Cox proportional hazards
regression.
Results
Evaluable
subjects included 325 women. With median follow-up of 34 months (range,
0.4–170), progression or recurrence was recorded in 241 (73.9%) and
death in 179 (54.9%). In multivariate analysis, predictors of reduced
planned RDI were: treatment off research protocols (odds ratio
[OR] = 4.3; P < 0.001) and BSA > 2 m2 (OR = 6.14; P < 0.001); predictors of reduced delivered RDI were: BMI over 30 kg/m2
(OR = 2.35; P = 0.008) and use of carboplatin (OR = 2.71; P = 0.008).
In multivariate analysis, the following factors were independently
associated with OS: delivered RDI < 85% (hazard ratio [HR] = 1.71;
P = 0.003) and elevated CA-125 at cycle 1 (HR = 2.29; P = 0.017).
Conclusion
In
this retrospective analysis, reduced chemotherapy RDI for ovarian
cancer was associated with lower OS, but not PFS, despite adjustment for
established prognostic factors.
Highlights
►
Relative dose intensity (RDI) is calculated as delivered dose intensity
divided by a literature-derived standard dose intensity.
► In this retrospective analysis, RDI less than 85% of standard was associated with lower overall survival. Calculation and reporting of RDI in future prospective trials would be informative to further investigate these findings.
► In this retrospective analysis, RDI less than 85% of standard was associated with lower overall survival. Calculation and reporting of RDI in future prospective trials would be informative to further investigate these findings.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.